NCT06253845View on ClinicalTrials.gov

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BIOLOGICAL

CG0070

CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with DDM and normal saline.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06253845 - Study of CG0070 After Transurethral Resection in Patients With IR NMIBC | Biotech Hunter | Biotech Hunter